BioSpace News Archive

Drug Development

BrainStorm’s ALS Drug NurOwn Heads to the FDA with Correction to Phase III Analyses

BrainStorm Cell Therapeutics said it will submit a Biologics License Application to the FDA for ALS hopeful NurOwn. Additionally, a correction has been made to analyses of the Phase III clinical trial.

August 14, 2022
·
5 min read
·
Heather McKenzie
Opthea Successfully Closes Well Supported US$90 Million Equity Financing

Opthea Limited is pleased to confirm it has received binding commitments for a successful two-tranche placement of new fully paid ordinary shares to institutional investors to raise approximately US$90 million1 at a price of A$1.15 per New Share, which represents a 12.6% discount to the 10-day Volume-Weighted Average Price as of 10 August 2022.

August 14, 2022
·
8 min read
Genetown

Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics to finance and advance the ongoing Phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration.

August 14, 2022
·
12 min read